Please login to the form below

Not currently logged in
Email:
Password:

cancer

This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche pulls EU Tecentriq/Avastin filing in kidney cancer. Another setback for Roche, but CHMP changes its mind on Opdivo/Yervoy. ... little longer before it can bring it forward for RCC, the most common form of kidney cancer.

Latest news

  • Roche builds on Immunocore ImmTAC deal Roche builds on Immunocore ImmTAC deal

    The trial is scheduled to start in early 2019, and will include a host of cancers, including non-small cell lung cancer (NSCLC), bladder cancer, head and neck cancer, gastric cancer ... Those molecules are based on soluble, engineered TCR’s, which

  • CHMP backs Sanofi’s all-oral sleeping sickness drug CHMP backs Sanofi’s all-oral sleeping sickness drug

    Johnson &Johnson got a positive opinion on its non-metastatic castration-resistant prostate cancer (CRPC) drug Erleada (apalutamide), setting up EU approval to follow its FDA green light earlier in the ... Among these, Novartis’CDK4/6 inhibitor Kisqali

  • AZ’s MYSTIC survival data is in – and it’s a bust AZ’s MYSTIC survival data is in – and it’s a bust

    Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and ... In the meantime, AZ also has trials of Imfinzi

  • AZ drug matched to cancer mutation passes phase 2 test AZ drug matched to cancer mutation passes phase 2 test

    AZ drug matched to cancer mutation passes phase 2 test. More data from promising class of targeted small molecule drugs. ... AKT E17K is present in about 1% of all tumours and is particularly common in prostate cancer.

  • Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

    Roche’ s Genetech nabs speedy review for Tecentriq in first-line breast cancer. ... Tecentriq in combination with nab-paclitaxel has the potential to meaningfully advance treatment for people with PD-L1-positive, metastatic triple-negative breast cancer

More from news
Approximately 646 fully matching, plus 1,612 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 8 fully matching, plus 245 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 199 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 38 fully matching, plus 216 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics